JP4475406B2 - 異常脂血症および他の脂質障害の治療用のＰＰＡＲα選択的化合物 - Google Patents

異常脂血症および他の脂質障害の治療用のＰＰＡＲα選択的化合物 Download PDF

Info

Publication number
JP4475406B2
JP4475406B2 JP2004524883A JP2004524883A JP4475406B2 JP 4475406 B2 JP4475406 B2 JP 4475406B2 JP 2004524883 A JP2004524883 A JP 2004524883A JP 2004524883 A JP2004524883 A JP 2004524883A JP 4475406 B2 JP4475406 B2 JP 4475406B2
Authority
JP
Japan
Prior art keywords
benzofuran
dihydro
carboxylic acid
chloro
phenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2004524883A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006500335A (ja
Inventor
シー，クオ・キユー
ジヤン，ヨン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2006500335A publication Critical patent/JP2006500335A/ja
Application granted granted Critical
Publication of JP4475406B2 publication Critical patent/JP4475406B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
JP2004524883A 2002-07-30 2003-07-25 異常脂血症および他の脂質障害の治療用のＰＰＡＲα選択的化合物 Expired - Lifetime JP4475406B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39952002P 2002-07-30 2002-07-30
PCT/US2003/023430 WO2004010936A2 (en) 2002-07-30 2003-07-25 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders

Publications (2)

Publication Number Publication Date
JP2006500335A JP2006500335A (ja) 2006-01-05
JP4475406B2 true JP4475406B2 (ja) 2010-06-09

Family

ID=31188592

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004524883A Expired - Lifetime JP4475406B2 (ja) 2002-07-30 2003-07-25 異常脂血症および他の脂質障害の治療用のＰＰＡＲα選択的化合物

Country Status (8)

Country Link
US (1) US7524882B2 (US07524882-20090428-C00062.png)
EP (1) EP1539136B1 (US07524882-20090428-C00062.png)
JP (1) JP4475406B2 (US07524882-20090428-C00062.png)
AT (1) ATE400564T1 (US07524882-20090428-C00062.png)
AU (1) AU2003256842B8 (US07524882-20090428-C00062.png)
CA (1) CA2491733A1 (US07524882-20090428-C00062.png)
DE (1) DE60322075D1 (US07524882-20090428-C00062.png)
WO (1) WO2004010936A2 (US07524882-20090428-C00062.png)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4475406B2 (ja) * 2002-07-30 2010-06-09 メルク・シャープ・エンド・ドーム・コーポレイション 異常脂血症および他の脂質障害の治療用のＰＰＡＲα選択的化合物
US7816385B2 (en) * 2002-12-20 2010-10-19 High Point Pharmaceuticals, Llc Dimeric dicarboxylic acid derivatives, their preparation and use
DK1599468T3 (da) 2003-01-14 2008-02-04 Arena Pharm Inc 1,2,3-trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser forbundet dermed såsom diabetes og hyperglykæmi
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONNECTION WITH CONDENSED RING
EP2287166A3 (en) 2003-07-14 2011-06-22 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2005024057A1 (en) * 2003-09-10 2005-03-17 Galapagos Genomics N.V. Method of identifying a compound that changes the amyloid-beta precursor protein processing in a cell
GB0403148D0 (en) * 2004-02-12 2004-03-17 Smithkline Beecham Corp Chemical compounds
BRPI0515015A (pt) 2004-08-11 2008-07-01 Kyorin Seiyaku Kk derivado cìclico de ácido aminobenzóico; medicamento; agonista ppar(alpha); agonista duplo ppar(alpha), y; agonista duplo ppar(alpha), (delta); modulador ppar; agente lipìdeo; agente profilático ou terapêutico compreendendo pelo menos um dos derivados cìclicos de ácido aminobenzóico ou sal do mesmo farmacêuticamente aceitável
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
CN101189231B (zh) * 2005-03-23 2011-05-18 杏林制药株式会社 环状氨基苯基链烷酸衍生物
EP2025674A1 (de) * 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JPWO2009087981A1 (ja) * 2008-01-11 2011-05-26 株式会社Kri 重合性化合物及びこの製造方法
SG188548A1 (en) 2010-09-22 2013-04-30 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
JPWO2014123205A1 (ja) 2013-02-06 2017-02-02 住友化学株式会社 縮合複素環化合物
EP3242666A1 (en) 2015-01-06 2017-11-15 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
CN108546245A (zh) * 2018-05-22 2018-09-18 绍兴文理学院 一种抗增殖活性中间体ml-098的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4205080A (en) * 1977-07-21 1980-05-27 Shell Oil Company 2,3-Dihydro benzofuran carboxamides
US4213999A (en) * 1979-06-07 1980-07-22 Shell Oil Company Inhibition of lipogenesis
US4213998A (en) * 1979-06-07 1980-07-22 Shell Oil Company Inhibition of lipogenesis
DE3265715D1 (en) * 1981-03-24 1985-10-03 Fisons Plc Anti srs-a carboxylic acid derivatives, processes for their production and pharmaceutical formulations containing them
JPS61158976A (ja) 1984-12-28 1986-07-18 Shionogi & Co Ltd ベンゾフランおよびベンゾチオフエン誘導体
FR2645537B1 (fr) * 1989-04-05 1994-03-04 Fabre Medicament Pierre Nouveaux sulfonamides derives d'acides benzocycliques ou benzoheterocycliques, leur preparation et leur application en therapeutique
US5273999A (en) * 1991-09-10 1993-12-28 Hoffmann-La Roche Inc. Carboxylic acid leukotriene B4 antagonists
US5352690A (en) * 1992-07-01 1994-10-04 Eli Lilly And Company 1,2,4-trioxygenated benzene derivatives useful as leukotriene antagonists
US5324743A (en) * 1992-12-10 1994-06-28 Eli Lilly And Company Leukotriene B4 antagonists
JP3187611B2 (ja) * 1993-05-17 2001-07-11 キヤノン株式会社 液晶性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた表示方法および表示装置
US5516917A (en) * 1994-06-08 1996-05-14 G. D. Searle & Co. Leukotriene B4 antagonists
AU2002248221B2 (en) * 2000-10-31 2006-08-17 Merck & Co., Inc. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
JP4475406B2 (ja) * 2002-07-30 2010-06-09 メルク・シャープ・エンド・ドーム・コーポレイション 異常脂血症および他の脂質障害の治療用のＰＰＡＲα選択的化合物

Also Published As

Publication number Publication date
AU2003256842A1 (en) 2004-02-16
EP1539136A4 (en) 2006-10-18
ATE400564T1 (de) 2008-07-15
EP1539136B1 (en) 2008-07-09
DE60322075D1 (de) 2008-08-21
CA2491733A1 (en) 2004-02-05
AU2003256842B8 (en) 2009-06-18
US7524882B2 (en) 2009-04-28
WO2004010936A3 (en) 2004-08-26
JP2006500335A (ja) 2006-01-05
EP1539136A2 (en) 2005-06-15
US20050228044A1 (en) 2005-10-13
WO2004010936A2 (en) 2004-02-05
AU2003256842B2 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
US6645997B2 (en) Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
JP4505327B2 (ja) 異常脂血症および他の脂質障害の治療用のＰＰＡＲα選択的化合物
US6713508B2 (en) Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
JP4475406B2 (ja) 異常脂血症および他の脂質障害の治療用のＰＰＡＲα選択的化合物
RU2328483C2 (ru) Индолы, обладающие противодиабетической активностью
JP2004513076A (ja) 糖尿病治療で有用なｎ−置換インドール類
AU2001292874A1 (en) Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
JP2004521124A (ja) 糖尿病および脂質障害用の２−アリールオキシ−２−アリールアルカン酸類
JP2003523336A (ja) 糖尿病及び脂質障害のためのアリールオキシ酢酸
AU2002248221A1 (en) Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
DE602005001265T2 (de) Antidiabetische oxazolidindione und thiazolidindione
EP1796665B1 (en) Compounds for the treatment of dyslipidemia and other lipid disorders
JP2008501027A (ja) 抗糖尿病活性をもつベンゾ尿素

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100209

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100302

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130319

Year of fee payment: 3